Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 6, 2016- These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 -
-
May 25, 2016- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -
-
Apr 27, 2016- Collaborations Will Work towards Predicting Medication Adherence -
-
Apr 1, 2016- Dupilumab is first systemic therapy to show positive Phase 3 results in patients with moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease marked by widespread rash, itching and associated psychosocial comorbidities -
-
Mar 29, 2016Pre-clinical immunogenicity and efficacy data published in Journal of Virology
-
Mar 4, 2016Praluent is now covered by most health insurance and Medicare plans
-
Feb 22, 2016- FDA decision anticipated in August 2016 -
-
Feb 12, 2016America's Leading National Consumer Research Survey Ranks ACT Advanced Care #1 in "Oral Care" Category
-
Feb 2, 2016Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids
-
Feb 2, 2016Six researchers each receive $1.625 million in "Pathway to Stop Diabetes®" awards
-
Jan 28, 2016- Aims to advance animal health though internet-connected technology and networks -
-
Dec 18, 2015Record-breaking holiday gift drive responds to increased homelessness rates
-
Dec 11, 2015Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies
-
Dec 1, 2015New 24 and 32-Packs Designed to Manage Dosage Regimens for both Latent and Active Tuberculosis
-
Nov 20, 2015- A study conducted with 1,500 Americans in July 2015 examined perceived risks of counterfeit medicines[1] -
-
Nov 10, 2015- 74 percent of patients reached their LDL cholesterol goals on 75 mg dose; Of the remaining patients whose dose was adjusted to 150 mg, most achieved their goal -
-
Nov 8, 2015- Data Show Significant Improvement in Signs and Symptoms and Physical Function in Rheumatoid Arthritis Patients who were Inadequate Responders to or Intolerant of TNF-Alpha Inhibitors (TNF-IR) -
-
Oct 29, 2015
-
Sep 29, 2015- First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data -
-
Sep 28, 2015- Crucial vaccination with Raboral V-RG® continues to help protect wildlife and people against this fatal disease
-
Sep 16, 2015New National Council on Aging Survey Shows Many Seniors Underestimate the Seriousness of the Flu, Largely Unaware of Vaccine Options1
-
Sep 14, 2015- LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone -
-
Aug 31, 2015- Will work together on new digital technology and tools for diabetes -
-
Jul 24, 2015- Praluent available early next week to U.S. patients -
-
Jul 14, 2015- Leading influenza vaccine manufacturer to distribute more than 65 million doses to help protect people six months and older against the flu -
-
Jun 30, 2015Sanofi and Regeneron Engage Academy Award® Winning Documentarian to Capture Behind-the-Scenes Look at Life with an Invisible Condition
-
Jun 8, 2015- ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -
-
May 21, 2015- Includes study in patients who were inadequate responders to, or intolerant of, TNF-alpha inhibitors -
-
May 18, 2015- Phase 3 Clinical Trial in Uncontrolled Persistent Asthma Underway -
-
May 11, 2015Despite CDC recommendations, fewer than 30% of teens received the second vaccination to help protect against meningococcal meningitis; new survey reveals potential reasons why
-
Apr 15, 2015U.S. Patent and Trademark Office Honors Sanofi for its Anti-Malarial Treatment
-
Mar 25, 2015Approval allows children to receive a combination of two recommended vaccinations
-
Mar 19, 2015- Results support resubmission of U.S. New Drug Application in Q3 2015 -
-
Mar 18, 2015Allergy sufferers are encouraged to share the #HappySmells they experience this season
-
Mar 15, 2015- Robust and consistent LDL-C lowering demonstrated with Praluent™ in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date -
-
Feb 18, 2015View the Interactive Maps on www.CholesterolCounts.com for a Snapshot of Cholesterol Awareness Across the U.S.
-
Feb 11, 2015America's Leading National Consumer Research Survey Ranks Gold Bond Products #1 in "U.S. Body Comfort and Relief" and "U.S. Skincare" Categories
-
Jan 20, 2015Further education about hypoglycemia and routinely monitoring blood glucose levels is needed
-
Jan 9, 2015- Primary efficacy endpoints met in two trials of alirocumab administered every four weeks -
-
Jan 6, 2015Awards will provide funding for innovative diabetes researchers
-
Dec 18, 2014Employees and contractors celebrate two decades of delivering essential items to Monroe County Head Start children and families
-
Dec 15, 2014New program will spotlight America’s high cholesterol numbers
-
Dec 12, 2014- The first and only four-strain influenza vaccine option administered intradermally -
-
Dec 2, 2014Sanofi Commitment to Research and Develop TB Treatments, Diagnostics and Vaccines Spans More than 50 Years
-
Nov 19, 2014- All six trials met primary efficacy endpoint -
-
Nov 18, 2014IcyHot SmartRelief System Provides Physical Therapist-Trusted TENS Technology for Persistent, Chronic Back Pain Relief That Starts at the Touch of a Button
-
Nov 11, 2014- Dupilumab Demonstrated Improvement in Lung Function, Reductions of Severe Exacerbations -
-
Nov 3, 2014- Includes New Data Showing Fluzone High-Dose Vaccine More Efficacious Than Standard-Dose Fluzone Vaccine -
-
Oct 16, 2014The two companies will develop a product jointly through phase II
-
Sep 18, 2014More Than $83,000 Raised Benefiting Boys & Girls Clubs of NEPA, Employment Opportunity and Training Center, and Marley’s Mission
-
Sep 17, 2014- Up to $200 Million Collaboration to Support Pioneering Science and New Treatments -
-
Sep 8, 2014Approval aligns with Centers for Disease Control and Prevention's recommendations for meningococcal vaccination
-
Aug 31, 2014- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial -
-
Aug 13, 2014- Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older -
-
Aug 13, 2014- Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older -
-
Aug 12, 2014Generics Division of Sanofi, Winthrop US, to Market the Drug
-
Jul 30, 2014- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor -